After hours

Jazz Pharmaceuticals plc

JAZZ · NASDAQ-GS

Analyst Consensus

Buy

19 analysts

$215

Current

—

Low

$300

Average

—

High

Average target implies +39.68% versus the current price.

Analyst Ratings Synthesis

A fully validated consensus cannot be established from the supplied evidence. StockAnalysis reports a Buy consensus from 19 analysts with an average target of $257, while Fintel reports an average target of $179.20 with a $121.20-$241.50 range and another Fintel page reports $190.69 with a $148.47-$241.50 range. These figures place the lower aggregator averages around $179-$191, but the reported spread reaches from $121.20 to $257. The evidence does not identify the analysts or firms behind the highest and lowest views, provide a dated revision history for the past week, or explain the substantive assumptions behind the target disagreement. No attributable rating actions are supplied.

Rating Actions

No individual rating actions have been captured for JAZZ yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

CANTOR FITZGERA

CO FORECST

H C WAINWRIGHT

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MORGAN STANLEY

NEEDHAM & CO.

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

STIFEL NICOLAUS

TD COWEN

TRUIST SECURITI

UBS

WELLS FARGO SEC

ZACKS RESEARCH

Symbol: JAZZ
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: Europe
Exchange: NASDAQ-GS

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease - often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide.

Key Issues

Bullish view

Revenue increased from $4.1 billion in FY2024 to $4.3 billion in FY2025, showing continued top-line growth that could support a return to profitability if expenses stabilize.

Bearish view

Despite the higher revenue base, Jazz reported a $0.4 billion net loss in FY2025 after earning $0.6 billion in FY2024, indicating that growth alone has not yet translated into earnings.

Analyst Consensus

See all

Buy

19 analysts

$215

Current

—

Low

$300

Average

—

High

Average target implies +39.68% versus the current price.

Earnings History

BeatMissNo estimate

Jazz Pharmaceuticals plc

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers